Shandong Xinhua Pharmaceutical Company Limited (XIN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shandong Xinhua Pharmaceutical Company Limited (XIN) has a cash flow conversion efficiency ratio of 0.012x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€56.11 Million ≈ $65.60 Million USD) by net assets (€4.70 Billion ≈ $5.50 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Shandong Xinhua Pharmaceutical Company L (XIN) market capitalisation for the company's overall valuation and market capitalisation.
Shandong Xinhua Pharmaceutical Company Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Shandong Xinhua Pharmaceutical Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shandong Xinhua Pharmaceutical Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Xinhua Pharmaceutical Company Limited ranked by their cash flow conversion efficiency. Explore Shandong Xinhua Pharmaceutical Company L cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Igis Value Plus Reit Co Ltd
KO:334890
|
N/A |
|
SPRINGFIELD PROP. LS-125
F:9MZ
|
N/A |
|
Surteco Group SE
XETRA:SUR
|
0.048x |
|
ISC Fresh Water Investment SOCIMI SA
MC:YISC
|
0.120x |
|
Oando PLC
JSE:OAO
|
-0.158x |
|
EDAP TMS S.A
F:EDA
|
1.144x |
|
Harbour Link Group Bhd
KLSE:2062
|
0.023x |
|
Agora S.A.
WAR:AGO
|
0.079x |
Annual Cash Flow Conversion Efficiency for Shandong Xinhua Pharmaceutical Company Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of Shandong Xinhua Pharmaceutical Company Limited from 2013 to 2025. View Shandong Xinhua Pharmaceutical Company L (XIN) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €5.46 Billion ≈ $6.38 Billion |
€533.73 Million ≈ $623.98 Million |
0.098x | +38.85% |
| 2024-12-31 | €5.22 Billion ≈ $6.10 Billion |
€367.61 Million ≈ $429.78 Million |
0.070x | +26.84% |
| 2023-12-31 | €4.78 Billion ≈ $5.58 Billion |
€265.28 Million ≈ $310.14 Million |
0.056x | -68.13% |
| 2022-12-31 | €4.35 Billion ≈ $5.09 Billion |
€758.24 Million ≈ $886.46 Million |
0.174x | +145.62% |
| 2021-12-31 | €3.65 Billion ≈ $4.27 Billion |
€259.12 Million ≈ $302.93 Million |
0.071x | -42.72% |
| 2020-12-31 | €3.39 Billion ≈ $3.96 Billion |
€420.19 Million ≈ $491.24 Million |
0.124x | +10.66% |
| 2019-12-31 | €3.11 Billion ≈ $3.64 Billion |
€348.27 Million ≈ $407.17 Million |
0.112x | -3.33% |
| 2018-12-31 | €2.80 Billion ≈ $3.27 Billion |
€323.91 Million ≈ $378.68 Million |
0.116x | -23.39% |
| 2017-12-31 | €2.58 Billion ≈ $3.02 Billion |
€389.97 Million ≈ $455.92 Million |
0.151x | -28.45% |
| 2016-12-31 | €2.08 Billion ≈ $2.43 Billion |
€439.35 Million ≈ $513.64 Million |
0.211x | +20.25% |
| 2015-12-31 | €1.98 Billion ≈ $2.32 Billion |
€348.64 Million ≈ $407.59 Million |
0.176x | -3.00% |
| 2014-12-31 | €1.91 Billion ≈ $2.24 Billion |
€346.34 Million ≈ $404.91 Million |
0.181x | +224.96% |
| 2013-12-31 | €1.88 Billion ≈ $2.20 Billion |
€104.99 Million ≈ $122.75 Million |
0.056x | -- |
About Shandong Xinhua Pharmaceutical Company Limited
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing service… Read more